Nektar Therapeutics announced its financial results for Q4 2025, reporting a net loss of $36.1 million, a stark contrast to a net income of $7.3 million in Q4 2024. Revenue decreased to $21.8 million from $29.2 million year-over-year, primarily due to the sale of its manufacturing facility.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.